Drug Profile


Alternative Names: gp75 DNA vaccine; GP75 MAb - Eli Lilly; IMC-GP75; Melanoma vaccine - ImClone Systems

Latest Information Update: 01 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Class Cancer vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 24 Nov 2008 Eli Lilly acquires ImClone Systems
  • 25 Jul 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 28 Oct 2004 No Development Reported - Preclinical for hTRPx3 for melanoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top